Kateryna Krytska - Concepedia

Concepedia

Author

Kateryna Krytska

University of Pennsylvania

Also Known As

K Krytska, K. Krytska, Kateryna Krytska, Kateryna krytska, Krytska, Kateryna V., Witek, Gabriela

164

Publications

1.8K

Citations

18

H-Index

28

Concepts

All Affiliations

University of Pennsylvania Children's Hospital of Philadelphia RTI International National Cancer Institute Thomas Jefferson University

KK

About

Kateryna Krytska is an author at University of Pennsylvania specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	524
2	Cell Biology	4	4	505
3	Immunology	4	4	141
4	Allergy	2	2	82
5	Cellular Physiology	1	1	63

Kateryna Krytska

×

21

Publications

1.8K

Citations

18

H-Index

	Year	Citations
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma Scott C. Bresler, Daniel A. Weiser, Peter J. Huwe, Cancer Cell MedicineReceptor Tyrosine KinasePathologyCancer GeneticsOncology	2014	383
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma Nicole R. Infarinato, Jin H. Park, Kateryna Krytska, Cancer Discovery	2015	180
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design Jo Lynne Rokita, Komal S. Rathi, Maria Cardenas, Cell Reports	2019	160
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination Jungoh Ham, Carlotta Costa, Renata Sano, Cancer Cell	2016	130
The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models Nathan M. Kendsersky, Jarrett M. Lindsay, E. Anders Kolb, Clinical Cancer Research	2021	117
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results Kelly C. Goldsmith, Julie R. Park, Kimberly Kayser, Nature Medicine	2023	112
Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma Kateryna Krytska, Hannah T. Ryles, Renata Sano, Clinical Cancer Research	2015	105
Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against Neuroblastoma Andrew Wood, Kateryna Krytska, Hannah T. Ryles, Clinical Cancer Research	2016	94
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models Caitlin D. Lowery, Michele Dowless, Matthew Renschler, Clinical Cancer Research	2018	79
Ozone inhalation induces exacerbation of eosinophilic airway inflammation and hyperresponsiveness in allergen‐sensitized mice S. Kierstein, Kateryna Krytska, S. Sharma, Allergy	2008	71

Page 1